(S)-2-N-propylamino-5-hydroxytetralin as a D3-agonist
The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.
1. A pharmaceutical composition comprising (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier or adjuvant, wherein the prodrug is of the formula
or a salt thereof;
wherein R 1 is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, —C(O)NR 2 R 3 , —C(O)NHR 2 , —P(O 2 H)OR 2 and —P(O 2 H)R 2 , wherein R 2 and R 3 are independently selected from H, C 1-6 alkyl, C 3-10 cycloalkyl, benzyl and phenyl and
wherein the at least one pharmaceutically acceptable carrier or adjuvant is selected from the group consisting of fillers, disintegrants, binders, lubricants, stabilizers, flavors, antioxidants, preservatives, dispersants, buffers and electrolytes; and
wherein the pharmaceutical composition is in a form selected from the group consisting of an infusion solution, an injection solution, an oil, a suppository, a patch, a microcapsule and a microparticle.
2. The composition of claim 1 , comprising (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt thereof.
3. The composition of claim 1 , comprising a prodrug or a salt thereof wherein R 1 is selected from C 1-6 alkylcarbonyl, C 3-10 cycloalkylcarbonyl, benzoyl, —C(O)NR 2 R 3 and —C(O)NHR 2 .
4. The composition of claim 1 , wherein the (S)-2-N-propylamino-5-hydroxytetralin or salt or prodrug thereof is present as a pure (S)-enantiomer.
5. A compound having the formula
or a salt thereof;
wherein R 1 is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, —C(O)NR 2 R 3 , —C(O)NHR 2 , —P(O 2 H)OR 2 and —P(O 2 H)R 2 , wherein R 2 and R 3 are independently selected from H, C 1-6 alkyl, C 3-10 cycloalkyl, benzyl and phenyl;
said compound being in the (S)-configuration; and
wherein said compound, when administered to a human body, is cleaved, processed or metabolized to (S)-2-N-propylamino-5-hydroxytetralin.
6. The compound of claim 5 , wherein R 1 is selected from C 1-6 alkylcarbonyl, C 3-10 cycloalkylcarbonyl, benzoyl, —C(O)NR 2 R 3 and —C(O)NHR 2 .